Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $28.08 and last traded at $26.11, with a volume of 2883 shares. The stock had previously closed at $25.19.
Analyst Upgrades and Downgrades
BCAX has been the topic of a number of recent analyst reports. TD Cowen assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating for the company. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock. Morgan Stanley assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price target for the company. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $43.33.
Read Our Latest Report on BCAX
Bicara Therapeutics Trading Up 1.0 %
Insider Buying and Selling
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Articles
- Five stocks we like better than Bicara Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Rising-Margin Stocks with Strong Growth Potential
- How to invest in marijuana stocks in 7 stepsÂ
- 3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.